PMC:7600245 / 8063-8190
Annnotations
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T47 | 84-87 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T48 | 113-121 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T61 | 30-34 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T62 | 103-112 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T61 | 0-127 | Sentence | denotes | The parenterally administered drug is being developed by Gilead Sciences, U.S., and has broad-spectrum antiviral activity [26]. |